News|Articles|June 2, 2026

FDA Sends CRL to Cingulate for CTx-1301

Listen

0:00 / 0:00

Key Takeaways

FDA’s CRL focused on CMC deficiencies, with no objections to clinical safety or efficacy, enabling a resubmission pathway primarily driven by manufacturing remediation.
The NDA was accepted in October 2025 with a May 31, 2026 PDUFA target, making the CRL a late-cycle regulatory setback rather than an early filing refusal.
CTx-1301 combines dexmethylphenidate with Precision Timed Release to deliver three programmed pulses, intended to mitigate midday symptom breakthrough seen with typical two-stage formulations.
Erosion Barrier Layer ‘tablet-in-tablet’ architecture uses Oralogik (licensed from BDD Pharma) to prevent premature drug release and time core exposure to predefined intervals.
Commercial positioning hinges on all-day, once-daily coverage in a crowded ADHD market; management cites ~$30 million cash to fund CMC fixes and operations into 2027.

FDA has issued a Complete Response Letter to Cingulate’s ADHD candidate CTx-1301 over manufacturing-related deficiencies, delaying approval of the once-daily therapy while leaving its clinical safety and efficacy profile unchallenged.

FDA issued a Complete Response Letter (CRL) to Cingulate for its investigational once-daily ADHD treatment CTx-1301, after the agency declined to approve the drug due to manufacturing-related concerns.

The CRL marks a setback that delays but does not derail the company's push to enter the ADHD market with a differentiated delivery platform.

“We are encouraged that the FDA’s response was limited to specific information requests related to CMC and did not currently identify any issues related to the clinical safety or efficacy of CTx-1301,” said Cingulate CEO Shane J. Schaffer.

The FDA previously accepted CTx-1301's NDA back in October 2025 with a PDUFA target action date of May 31, 2026, making the CRL a late-stage setback rather than an early-stage rejection, and one the company believes it can resolve without additional clinical work.

FDA Approves Hepcludex as First and Only Approved Treatment for Chronic Hepatitis Delta Virus

FDA Approves Breztri for Patients 12 Years and Older with Asthma

FDA Approves Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy

Why did FDA issue a CRL?

According to Reuters, the CRL cited chemistry, manufacturing, and controls deficiencies. As with several other recent CRLs in the industry, the FDA did not raise any concerns about CTx-1301's safety or effectiveness, a distinction Cingulate was quick to highlight.¹ The company says its planning to address the outstanding requests promptly and move efficiently toward resubmission.

"Our immediate priority is to complete the CMC and we believe the outstanding requests will be addressed quickly as we move efficiently toward resubmission," said Schaffer. He continued to say that the company has nearly $30 million in cash, which is expected to help support the resubmission process and operations heading into 2027.¹

What is CTx-1301?

CTx-1301 is a once-daily tablet formulation of dexmethylphenidate, the active ingredient also used in Novartis's Focalin XR, built on Cingulate's proprietary Precision Timed Release platform (PTR).²

Where existing dexmethylphenidate products typically use a two-stage release mechanism, CTx-1301 is designed to deliver three precisely timed releases across the day using an Erosion Barrier Layer (EBL) technology that controls drug release at predefined intervals with no premature release.² The design aims to address the midday wear-off that limits the effectiveness of existing ADHD treatments and improve adherence by covering the full active day in a single dose.

Cingulate’s innovative PTR drug delivery platform technology incorporates the EBL that provides control of drug release at precise, pre-defined times with no release of drug prior to the intended release.² The EBL technology is encased around a drug-containing core, giving a tablet-in-tablet dose form and is designed to erode at a controlled rate until the drug is released from the core tablet. The EBL formulation, Oralogik, is licensed from BDD Pharma.²

What market would CTx-1301 enter?

If approved following resubmission, CTx-1301 is expected to enter a well-established and competitive ADHD market that includes several established competitor products. Cingulate's differentiation case rests on the three-pulse release profile, which it argues more closely mirrors the duration of a full school or workday than existing alternatives.¹

Sources

FDA declines to approve Cingulate's ADHD treatment over manufacturing issues Reuters June 2, 2026 https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-cingulates-adhd-drug-2026-06-02/
Cingulate Receives Complete Response Letter from FDA for CTx-1301 Cingulate June 2, 2026 https://www.globenewswire.com/news-release/2026/06/02/3305119/0/en/Cingulate-Receives-Complete-Response-Letter-from-FDA-for-CTx-1301.html

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.